Objective measure of medication adherence: Cholesterol (low‐density lipoprotein) · people prescribed medication for primary prevention of cardiovascular disease
1 finding from 1 review
Objective measure of medication adherence: Blood pressure · people prescribed medication for primary prevention of cardiovascular disease
1 finding from 1 review
Combined cardiovascular events · people prescribed medication for primary prevention of cardiovascular disease
1 finding from 1 review
Adverse events · people prescribed medication for primary prevention of cardiovascular disease
1 finding from 1 review
Cognitive outcome: satisfaction with treatment · people prescribed medication for primary prevention of cardiovascular disease
1 finding from 1 review
Outcomes Length of intervention in weeks (Median, (IQR)) · people with congenital heart disease.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiorespiratory fitness (CF) (mL/kg/min) · people with congenital heart disease.
1 finding from 1 review
Health‐related quality of life (HRQoL) · people with congenital heart disease.
1 finding from 1 review
Physical activity · people with congenital heart disease.
1 finding from 1 review
Submaximal cardiorespiratory fitness · people with congenital heart disease.
1 finding from 1 review
Muscle strength · people with congenital heart disease.
1 finding from 1 review
Adverse events (12 (12, 26)) · people with congenital heart disease.
1 finding from 1 review
Hospital admissions · people with congenital heart disease.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Myocardial infarction · people with or without existing cardiovascular disease, men and women
Homocysteine‐lowering interventions (high dose) showed no clear difference in myocardial infarction compared with homocysteine‐lowering interventions (low dose) (moderate certainty).
1 finding from 1 review
Stroke · people with or without existing cardiovascular disease, men and women
It is very uncertain whether homocysteine‐lowering interventions (high dose) changes stroke compared with homocysteine‐lowering interventions (low dose) (very low certainty).
1 finding from 1 review
Death by any cause · people with or without existing cardiovascular disease, men and women
Homocysteine‐lowering interventions (high dose) showed no clear difference in death by any cause compared with homocysteine‐lowering interventions (low dose) (moderate certainty).
1 finding from 1 review
Cancer · people with or without existing cardiovascular disease, men and women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardio‐respiratory fitness: 12 months Sub maximal assessment of cardio‐respiratory fitness · patients with promoting physical activity
1 finding from 1 review
Physical activity · patients with promoting physical activity
Face‐to‐face interventions showed no clear difference in dichotomous outcomes: 12 months Self‐reported PA questionnaire compared with control (high certainty).
4 findings from 1 review
OR 1.58 [0.91, 2.75]
3 studies · 3261 participants
High
OR 1.19 [1.02, 1.39]
1 study · 2701 participants
High
no estimate extracted
3 studies · 4235 participants
High
Show 1 more finding
Short‐term impact (< 12 months) child vegetable intake · children aged 5 years and under
1 finding from 1 review